Health Care & Life Sciences » Biotechnology | Nymox Pharmaceutical Corp.

Nymox Pharmaceutical Corp.

Nymox Pharmaceutical Corp.
Stock Exchange Frankfurt Stock Exchange
EPS
 -
Market Cap
 -
Shares Outstanding
 60.74 M
Public Float
 31.09 M
Nymox Pharmaceutical Corp.
Stock Exchange NASDAQ Stock Market
EPS
 $0.17
Market Cap
 $97.45 M
Shares Outstanding
 67.68 M
Public Float
 37.98 M

Profile

Address
Bay & Deveaux Streets
Nassau NW
Bahamas
Employees -
Website http://www.nymox.com
Updated 07/08/2019
Nymox Pharmaceutical Corp.operates as a biopharmaceutical company, which engages in the research and development on products for the aging population. Its products include NicAlert and TobacAlert, and the NX-1207 for the treatment of low-grade localized prostate cancer. It operates through the following geographical segments: Canada, United States, and Europe.

Financials

View All
Created with Highcharts 5.0.14Nymox Pharmaceutical Corp.Net Income. Fiscal year is January-December. All values USD Thousands.4 9084 9084 5944 59417 88317 88313 11013 11013 42913 42910 59410 59420132014201520162017201805k10k15k20k
Created with Highcharts 5.0.14Nymox Pharmaceutical Corp.Sales/Revenue. Fiscal year is January-December. All values USD Thousands.3 3593 3592 9492 9492 7612 76128428422422429929920132014201520162017201801k2k3k4k

Paul Averback
Chairman, President & Chief Executive Officer
Randall Lanham
Secretary, Director & General Counsel
View All

StatInvestor

Privacy Policy
Feedback

© 2025 StatInvestor All Rights Reserved.